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ABSTRACT
Background: Although metronidazole is the drug of choice for treatment of trichomoniasis, resistant Trichomonas vaginalis isolates have
been identified. Aim of the study: So,
the aim of our study is to investigate
the in vitro susceptibility of T. vaginalis against metronidazole in our locality.
Methods: Vaginal swabs were
collected from 420 cases attending
the outpatients’ clinics of
the
gynecology department, Mansoura
university hospital. The patients
were subjected to wet mount smear
examination and Giemsa staining
193
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followed by culture on modified
Diamond’s media. In vitro susceptibility testing was done for 49 trichomonas vaginalis positive cases to
determine minimal lethal concentration (MLC) of metronidazole in each
case.
Results: Most susceptible isolates
(34.7%) were dead at MLC 1 µg\ml
followed by MLC 2 µg\ml at which 8
(16.3%) isolates were killed, followed
by 6 (12.2%) isolates at 4 µg\ml, 7
isolates (14.2%) at 8 µg\ml, 4 isolates (8.1%) at 16 µg\ml, and 3
(6.1%) isolates at 32 µg\ml while in
resistant isolates 2 were killed at
concentration 64 µg\ml and 2 isoMANSOURA MEDICAL JOURNAL
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lates were sensitive at concentration
128 µg\ml.
Conclusion: In our locality, most
isolates were susceptible to low
dose of metronidazole (lower than or
equal 32 µg/ml)with few resistant isolates that could be explained by development of drug resistance in future.
Keywords: Trichomonas vaginalis, Metronidazole, Resistance, Susceptibility, in vitro
biochemical
testing.

INTRODUCTION
Trichomoniasis, the clinical disease refers to the T. vaginalis pathogen, has become the most prevalent
non-viral sexually transmitted infection (STI) in the United States [1] .
The worldwide incidence of trichomoniasis was estimated to be 276.4
million new cases per year in 2008
[2]. In Egypt, the reported rate of
prevalence ranges from 5% to
79.16% [3].
In women, trichomoniasis has a
wide spectrum of clinical presentations ranging from asymptomatic to
acute, or subacute vaginitis with malodorous vaginal discharge [4]. Other

symptoms include dysuria, dyspareunia, or vulvovaginal soreness. Common signs include vulvovaginal erythema, frothy yellowish-gray vaginal
discharge, increase pH of the vagina
(>6), and rarely a strawberry cervix
[5]. Infection may be complicated
with preterm labor and increased
perinatal morbidity [6].
Diagnosis of T. vaginalis is established by the traditional wet mount
test, in which "corkscrew" motility is
observed [7]. Culture has long been
the gold standard for diagnosing T.
vaginalis infection, with a sensitivity
range from 85-95% [8]. Other used
methods for diagnosis include enzyme-linked immunosorbent assay,
staining methods, latex agglutination, and nucleic acid amplification
tests. [9]
Metronidazole is the drug of
choice for the treatment of trichomoniasis. A single oral dose of 2-g
achieves a cure rate of 90-95% [10].
Low-level resistance of T. vaginalis
to metronidazole has been reported
in a range of 2-5% [11].
Metronidazole
resistance
is
defined clinically as failure to cure infection after two successive courses
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of treatment. Once other causes of
treatment failure have been ruled out
including medication noncompliance
and reinfection, the possibility of a
resistant vaginal trichomoniasis must
be considered [12]. Although various
therapeutic regimens have been developed and recorded, there is no
consensus on therapy for metronidazole resistant vaginal trichomoniasis
[13].
The aim of this work is to detect
the magnitude of T. vaginalis resistance.to metronidazole in our locality
and its implications on patients’ outcome.

SUBJECTS & METHODS
2.1. Study design
The study was carried out in Medical Parasitology Department Faculty
of Medicine, Mansoura University
and Gynecology outpatient clinic of
Mansoura University Hospital, during
the period from December 2013 to
February 2016.
2.2. Patients’ selection
A total of 320 symptomatic female
patients were included in this study.
Another 100 patients were included
in the study screening for trichomonas vaginalis in non-symptomatic patient.

195

Criteria for symptomatic patients:
Women in their childbearing age
(18:45years) who complained of vaginal discharge of any type, itching,
burning sensation or both, and with
any other gynecological manifestations suggestive of trichomoniasis
such as dyspareunia and or dysuria.
Criteria for asymptomatic patients: Patients matching the same
age group were included.
Exclusion criteria: Pregnant women, during menstruation, vaginal
douching for at least 2–3 days before the day of examination.
3.2. Data and sample collection
An informed written consent was
obtained from each patient after explanation of the procedure and all
experiments have been examined
and approved by Mansoura University ethics committee.
History taking included age, parity, presenting symptoms such as
vaginal discharge, bad odor, itching,
dysuria, dyspareunia, burning sensation and post coital bleeding, also
obstetric history as regard delivery of
low birth weight infant and preterm
delivery
MANSOURA MEDICAL JOURNAL
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Clinical examination involved per
vaginal (PV) non lubricated dry sterile speculum for each case to obtain
two vaginal swab.

Subculture was usually done every
48h by adding 0.3 ml from the suspension to fresh tube containing culture media [16].

4.2. Methods
Two Vaginal specimens were collected using sterile cotton swab from
the posterior fornix during speculum
examination to be examined as following : one swab for wet mount microscopic examination according to
Mahmoud et al [14]. Swab was mixed
in 1:2 ml phosphate buffer saline solution and then examined microscopically under dark ground illumination
for evidence of motile trichomonas
vaginalis within 0.5 – 3 hours after
sampling time ( Figure 1).

5.2. In vitro resistance tests
We used metronidazole vial
(Amerizole) (Amriya for pharmaceutical industries) each 100 ml contain
500mg
metronidazole. Drug susceptibility test was carried out by
aerobic tube assay method as
described by Kulda et al [17]. Metronidazole was used in our study in a
serial dilution at concentration of
1,2,4,8,16,32,64,128,256 µg/ml. The
assay was run twice with drug free
media as standard control. Haemocytometer count was made with 48h
old culture of trichomonads to obtain
the desired number (1x104 trophozoite /ml).

The other swab used for culture
of T. vaginalis on Modified Diamond
medium [15]. The medium was supplemented with 10% heat inactivated
bovine serum. Microorganisms were
eliminated by the aid of sodium penicillin G, streptomycin sulphate, amphotericin. All strains were maintained in 10 ml screw cap glass tube
at 37°C. The detection of T. vaginalis
trophozoites was considered if object
of approximately 7 to 10 µm in diameter was observed showing the characteristic jerky motility (Figure 2).

Each one of 9 culture tubes were
inoculated with 104 trophozoites,
and the different concentrations of
the drug were added to each isolate
with a final volume of 2 ml per tube
and incubated at 37°C under aerobic
conditions for 48 hours. The control
tubes for each isolate were incubated simultaneously under the same
conditions, the drug susceptibility of
the different isolates was recorded
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by determining the minimal lethal

RESULTS

concentration (MLC), which is de-

From 320 Symptomatic patients,
44 (13.8%) patients were positive for
infection with T. vaginalis and from
100
asymptomatic
patients
5
(5%)patient was positive for infection
as shown in (Table 1.). There is high
percent in the presence of T. vaginalis infection in symptomatic cases
vs. asymptomatic cases (13.8% vs.
5%; P0.02), and the difference was
statistically significant, the overall
prevalence of T. vaginalis among the
studied cases was (11.7%).

fined as the lowest drug concentration at which no motile organisms
were observed [17, 18]. The viability
of the parasite was assessed by reculture of the inoculate previously
exposed to the drug in drug-free media [17]. Metronidazole resistance
case was defined as aerobic MLC≥
50 µg/ml [18, 19].
6.2. Statistical analysis
Data were analyzed on a personal

computer

running

IBM-SPSS

for windows “Statistical-Package for
Social-Scientists”

Release-22. Sta-

tistical tests were

two-tailed.

A

p-value < 0.05 was interpreted as
statistically significant. For description of qualitative variables, the frequency distribution was utilized with
tabulation including the number of
cases and percentage. For description of measurable parameters, the
mean, and standard-deviation were
used to show central tendency and
dispersion. Relations between categorical variables were tested by the
Chi-Square Test (X2). Fishers’ exact-test was utilized when the prerequisites of Chi-square test were violated.

The mean age of studied cases
as shown in Table 2 was 32±5.6
years, T. vaginalis positive cases
were more prevalent among age
group 26-35 years (53.1%). The difference between presence and absence of T. vaginalis among different
age groups was of no statistically
significant difference (p =0.08).
As shown in (Table 3), (From 44
symptomatic (40 susceptible and 4
resistant) not include 5 cases which
is asymptomatic) percent of typical
type of discharge is higher in resistant than susceptible cases. The difference reveal high statistically significant difference (100% vs. 7.5%;
P=>0.001).
MANSOURA MEDICAL JOURNAL
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According to (Table 4), (From 44
symptomatic patients from which
there was 1 patient widow and one
patient divorced (40 susceptible and
4 resistant) not include 5 cases
which is asymptomatic) post coital
bleeding and pain were significantly
higher in resistant cases.

ceptible at MLC 1 µg\ml followed by
MLC 2 µg\ml at which 8/49 (16.3%)
isolates were died, followed by 6/49
(12.2%) isolates at 4 µg\ml, followed
by 7/49 isolates (14.2%) at 8 µg\ml,
followed by 4/49 isolates (8.1%) at
16 µg\ml, followed by 3/49 (6.1%)
isolates at 32 µg\ml while in resistant
isolates 2 were died at concentration

Table 5 from total 49 positive
symptomatic and asymptomatic cases, there was a high percent in presence of preterm delivery in resistant
than susceptible cases (50% vs.
2.2%) and the difference was statistically significant (p=0.015). Also,
there was a high percent in presence
of low birth weight infant in resistant
than susceptible cases (50 vs. 4.4%)
and the difference was statistically
significant (p =0.03).

64 µg\ml and 2 isolates were died at
concentration 128 µg\ml and no isolates were died at concentration 256
µg\ml.
The prevalence of low-level metronidazole resistance was (4.1%)
and the prevalence of mild to moderate resistance was (4.1%) according
to Kissinger et al [19], degree of resistance was detected as follow, mild
resistance occurs with MLCs of

In the present study, MLC of different concentration of metronidazole under aerobic condition after 48
h incubation period as shown in Figure 3 was as following, most susceptible isolates 17/49 (34.7%)were sus-

50:100 µg/mL, mild-to moderate resistance occur with MLCs of 101:199
µg/mL, moderate resistance occurs
with MLCs of 200:400 µg/mL and
high resistance occur with MLCs of
400 µg/mL of isolates.
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Figure. 1: Shows T. vaginalis trophozoite
in wet mount preparation
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Figure. 2: T. vaginalis observed in Modified Diamond's culture
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DISCUSSION
Trichomonas vaginalis is a parasite of the urogenital tract of human,
with a worldwide occurrence and significant implications for global public
health. It has been implicated with
preterm labor, pelvic inflammatory
disease, cervical intraepithelial neoplasia [20].
The overall prevalence of T. vaginalis among women included in
this study was 11.7% (49/420),
among symptomatic woman was
13.8% (44/320) and among asymptomatic woman was 5% (5/100). This
corroborates findings by a previous
study from Benha the prevalence of
T. vaginalis in this study was 11%,
[21]. However, higher rates of infection were recorded in Cairo and
Mansoura with prevalence of 23%
and 38.37%, respectively [22, 23]. On
the other side, studies from Africa,
Iraq and Cairo demonstrated a lower
prevalence of T. vaginalis infection
ranging from 4.1%- 5.4% [14, 24, 25]
The variations in the prevalence
of infection related to many factors
including age, sexual activity, number of sexual partners, other sexually
transmitted diseases, menstrual cycle phases, examination techniques,

specimen collection, sample size, inclusion and exclusion criteria and laboratory technique. Also, may be
due to socio-demographic characters
of the communities that change from
a country to another and from a society to another [26].
In this study the Infection was
considerably more common in symptomatic than in asymptomatic women
with statistically significant difference
(13.8% vs. 5%; P0.02), and this finding matched with other study [27]
The mean age of studied cases
was 32±5.6 years, T. vaginalis positive cases were more prevalent
among age group 26-35 years
(53.1%), followed by age group 3645 years (28.6%), followed by age
group 18-25 years (18.3%).
In the present study, percent of
typical type of discharge is higher in
resistant than susceptible cases and
the difference was of high statistical
significance
(100%
vs.
7.5%;
P=>0.001), also there was a high
percent in the presence of post coital
bleeding in resistant versus susceptible cases and the difference between was statistically significant
(7.9% vs. 75%; P= 0.007), also there
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was a high percent in the presence
of lower abdominal pain in resistant
versus susceptible cases and the difference between was statistically significant (40% vs. 100%; P= 0.03),
also there was a high percent in
presence of low birth weight infant in
resistant than susceptible cases (50
vs. 4.4%) and the difference between was statistically significant (p
=0.03)
To our Knowledge this is the first
study to compare the susceptible
and resistant isolates of T. vaginalis
from the previous point of view and
from this result it will be a valuable
finding used to suspect resistant T.
vaginalis isolates in patient with profuse frothy yellow to gray malodourous discharge [28], post coital bleeding, lower abdominal pain, history of
preterm delivery and low birth weight
infant especially if all present in combination.

From the previous finding the
prevalence of resistance in our study
was 8.2%, this finding correlate with
other study in US where 9.6% only
were resistant to metronidazole
among total Trichomoniasis cases
[11]. Variation in susceptibility was
also reported in other studies [29].
The prevalence of low-level metronidazole resistance was (4.1%)
and the prevalence of mild to moderate resistance was (4.1%), this was
in agreement with other study as regard low level resistance [30].

Conclusion
•

•

According to Narcisi and Secor
[18], in an aerobic 48 hours assay in

the present study T. vaginalis isolates with MLC of 32 µg/ml and less
were considered susceptible to metronidazole, while those with MLC of
64 µg/ml and greater were considered resistant.

203

•

•

T. vaginalis resistance to metronidazole is an announcing problem in the world, the incidence
rate of metronidazole resistance
is 8.2% in our locality.
The presence of typical discharge, pain and post-coital
bleeding point are significantly associated with resistance to metronidazole.
T. vaginalis resistance to metronidazole is associated with significantly higher obstetric complications including preterm labor and
low birth weight.
It is recommended to do a pharmacokinetic study of metronidaMANSOURA MEDICAL JOURNAL
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zole to detect its level in the vaginal mucosa; a concentration higher than 64ug/ml at 48 hours is
needed to overcome resistance.
Searching for another drug in T.
vaginalis resistance should be
considered in this prospect.
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